Table 2.
Details of antiretroviral regimes followed by human immunodeficiency virus (HIV)-infected women on therapy
| Antiretroviral regime | n/total | % |
|---|---|---|
| Lamivudine/stavudine/efavirenz | 11/41 | 26·8 |
| Combivir (lamivudine/zidovudine)/efavirenz | 9/41 | 22·0 |
| Lamivudine/zidovudine/efavirenz | 4/41 | 9·8 |
| Combivir (lamivudine/zidovudine)/nevirapine | 4/41 | 9·8 |
| Lamivudine/nevirapine | 3/41 | 7·3 |
| Lamivudine/nevirapine/zidovudine | 2/41 | 4·9 |
| Kaletra (lopinavir/ritonavir)/efavirenz | 2/41 | 4·9 |
| Lamivudine/stavudine/nevirapine | 1/41 | 2·4 |
| Kaletra (lopinavir/ritonavir)/zidovudine | 1/41 | 2·4 |
| Kaletra (lopinavir/ritonavir)/nevirapine | 1/41 | 2·4 |
| Efavirenz/zidovudine | 1/41 | 2·4 |
| Efavirenz/stavudine | 1/41 | 2·4 |
| Nevirapine/zidovudine | 1/41 | 2·4 |